PuSH - Publikationsserver des Helmholtz Zentrums München: Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidycholines.

Navigation

Startseite

English

Recherche

Erweiterte Suche

Durchblättern nach ...

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Erscheinungsjahr

Publikationen im Überblick

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Hotze, M.* ; Baurecht, H.* ; Rodriguez, H.* ; Chapman-Rothe, N.* ; Ollert, M.* ; Fölster-Holst, R.* ; Adamski, J. ; Illig, T.* ; Ring, J.* ; Weidinger, S.*

Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidycholines.

Allergy 69, 132-135 (2014)

DOI

PMC

Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.

Abstract
Metriken
Zusatzinfos

Omalizumab, a monoclonal antibody targeting IgE, is an established therapy for severe allergic asthma and has shown efficacy in chronic spontaneous urticaria. Small-scale studies indicated some beneficial effect also in atopic dermatitis (AD). To evaluate the efficacy of omalizumab in AD and to identify markers associated with treatment response, we conducted a prospective 28-week open-label trial on 20 adults with moderate-to-severe AD. Our results confirm previous observations of a positive response in a subgroup of patients and suggest that responders are characterized by the absence of filaggrin mutations and altered lipid metabolite profiles with high levels of various glycerophospholipids.

Altmetric

Weitere Metriken?

[➜Einloggen]